Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, Andy C. Rawstron et al.|New England Journal of Medicine|2023Cited by 155
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patientsMatthew R. Wilson, Fiona Miall, Marie‐Pierre Moles‐Moreau et al.|UCL Discovery (University College London)|2022Cited by 76
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryMatthew R. Wilson, Pam McKay, Nicolás Martínez‐Calle et al.|Blood Advances|2020Cited by 54
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Andy C. Rawstron et al.|New England Journal of Medicine|2025Cited by 26